1
|
Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JCH, Garrido P. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey. ESMO Open 2023; 8:100781. [PMID: 36842299 PMCID: PMC10163010 DOI: 10.1016/j.esmoop.2023.100781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 01/04/2023] [Accepted: 01/04/2023] [Indexed: 02/26/2023] Open
Abstract
BACKGROUND Following a European Society for Medical Oncology Women for Oncology (ESMO W4O) survey in 2016 showing severe under-representation of female oncologists in leadership roles, ESMO launched a series of initiatives to address obstacles to gender equity. A follow-up survey in October 2021 investigated progress achieved. MATERIALS AND METHODS The W4O questionnaire 2021 expanded on the 2016 survey, with additional questions on the impact of ethnicity, sexual orientation and religion on career development. Results were analysed according to respondent gender and age. RESULTS The survey sample was larger than in 2016 (n = 1473 versus 482), especially among men. Significantly fewer respondents had managerial or leadership roles than in 2016 (31.8% versus 51.7%). Lack of leadership development for women and unconscious bias were considered more important in 2021 than in 2016. In 2021, more people reported harassment in the workplace than in 2016 (50.3% versus 41.0%). In 2021, ethnicity, sexual orientation and religion were considered to have little or no impact on professional career opportunities, salary setting or related potential pay gap. However, gender had a significant or major impact on career development (25.5% of respondents), especially in respondents ≤40 years of age and women. As in 2016, highest ranked initiatives to foster workplace equity were promotion of work-life balance, development and leadership training and flexible working. Significantly more 2021 respondents (mainly women) supported the need for culture and gender equity education at work than in 2016. CONCLUSIONS Gender remains a major barrier to career progression in oncology and, although some obstacles may have been reduced since 2016, we are a long way from closing the gender gap. Increased reporting of discrimination and inappropriate behaviour in the workplace is a major, priority concern. The W4O 2021 survey findings provide new evidence and highlight the areas for future ESMO interventions to support equity and diversity in oncology career development.
Collapse
Affiliation(s)
- H Linardou
- 4th Oncology Department & Comprehensive Clinical Trials Centre, Metropolitan Hospital, Athens, Greece.
| | | | - J Bajpai
- Tata Memorial Centre, Homi-bhabha National Institute, Mumbai, India
| | - S Banerjee
- The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK
| | - A S Berghoff
- Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria
| | | | - S P Choo
- Curie Oncology Singapore, National Cancer Centre Singapore
| | - R Dent
- National Cancer Center Singapore, Duke-NUS Medical School, Singapore
| | - E Felip
- Medical Oncology Department, Vall d'Hebron University Hospital, Thoracic Oncology and H&N Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain
| | | | - M C Garassino
- University of Chicago Medicine & Biological Sciences, Section of Hematology/Oncology, Chicago, USA
| | - E Garralda
- Early Drug Development Unit, VHIO-Vall d'Hebron Institute of Oncology, HUVH-Vall d'Hebron University Hospital, Barcelona, Spain
| | | | - A Letsch
- Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A M Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - D Mukherji
- Clemenceau Medical Center Dubai, Dubai, United Arab Emirates
| | - S Peters
- Oncology Department-CHUV, Lausanne University, Lausanne
| | - C Sessa
- Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - J Tsang
- Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - J C-H Yang
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
| | - P Garrido
- Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
| |
Collapse
|
2
|
Das GM, Kulkarni S, Oturkar C, Edge SB, Wilton JH, Wang J, Swetzig WM, Adjei AA, Bies R, Hutson AD, Morrison CD, Kaipparettu BA, Groman A, Kumar S, Capuccino H. Abstract P5-04-04: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Das GM, Kulkarni S, Oturkar C, Edge SB, Wilton JH, Wang J, Swetzig WM, Adjei AA, Bies R, Hutson AD, Morrison CD, Kaipparettu BA, Groman A, Kumar S, Capuccino H. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-04.
Collapse
Affiliation(s)
- GM Das
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - S Kulkarni
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - C Oturkar
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - SB Edge
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - JH Wilton
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - J Wang
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - WM Swetzig
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - AA Adjei
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - R Bies
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - AD Hutson
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - CD Morrison
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - BA Kaipparettu
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - A Groman
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - S Kumar
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - H Capuccino
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| |
Collapse
|
3
|
Yeboah ED, Hsing AW, Mante S, Mensah JE, Kyei MY, Yarney J, Vanderpuye V, Beecham K, Tettey Y, Biritwum RB, Adjei AA, Gyasi R, Asante K, Ampadu KN, Klufio GO, Gepi-Attee S, Owoo C, Kwami D, Ahiaku, Pandra R, Cook MB. MANAGEMENT OF PROSTATE CANCER IN ACCRA, GHANA. J West Afr Coll Surg 2016; 6:31-65. [PMID: 29181364 PMCID: PMC5667721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/13/2023]
Abstract
INTRODUCTION Africans living with prostate cancer in Africa face problems of early diagnosis and appropriate treatment. AIM To study the clinical incidence of prostate cancer, risk factors, TNM stage, their management and outcomes. METHODS A prospective study of Prostate Cancer cases managed at Korle Bu Teaching Hospital and hospitals in Accra, diagnosed by history, abnormal PSA/DRE, physical examination and histologically confirmed by biopsy from 2004 to 2013 was carried out. The cases were TNM staged and managed by approved protocol. RESULTS There were 669 cases with a mean age 70±0.045SE years, median Gleason Score of 7, organ confined Prostate Cancer(PC) in 415(62%), locally advanced in 167(25%) and metastatic Prostate Cancer in 87(13%) cases. The cases were followed for median of 10 months to ≥ 84 months. Organ confined cases were managed by: Radical Prostatectomy (RP) 92 (13.8%) with a mortality of 0.3%; brachytherapy 70 (10.5%) with a mortality of 0.1% and External Beam Radiotherapy (EBRT) 155 (23%) with a mortality 0.7%. In all, 98 men constituting (14.1%) cases with a mean age of 75+0.25SE years, life expectancy <10 years were treated by hormonal therapy with a mortality of 1.7%. Twenty cases who were for active surveillance (GS6), PSA <10ng/ml, life expectancy <10 years later all opted for EBRT. Locally advanced cases 25% all had neoadjuvant hormonal therapy then Brachytherapy in 3 (0.4%) mortality 0.15% and EBRT in 64 (9.5%), mortality 0.59%. Hormonal therapy was given in 100 (15%) locally advanced cases, mortality 5%. Metastatic prostate cancer cases (13%) were managed by hormonal therapy, mortality 6%. CONCLUSION Improved facilities and dedicated skilled teams led to a significant rise in proportion of organ confined Prostate Cancer from 15.3% to 62% curable by Radical Prostatectomy, brachytherapy or EBRT with longer disease free survival.
Collapse
Affiliation(s)
- E D Yeboah
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - A W Hsing
- Stanford University - Stanford Cancer Institute, CA, USA
- Division of Cancer Epidemiology and Genetics, National Cancer Institute(NCI),National Institute of Health(NIH), Bethesda, Maryland, USA
| | - S Mante
- 37 Military Hospital, Accra, Ghana
| | - J E Mensah
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - M Y Kyei
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - J Yarney
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - V Vanderpuye
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - K Beecham
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - Y Tettey
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - R B Biritwum
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - A A Adjei
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - R Gyasi
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - K Asante
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - K N Ampadu
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - G O Klufio
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - S Gepi-Attee
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - C Owoo
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | - D Kwami
- University of Ghana Medical School(UGMS), Korle Bu Teaching Hospital(KBTH), Accra, Ghana now University of Ghana School of Medicine and Dentistry(UGSMD), Accra, Ghana
| | | | - R Pandra
- Visiting Surgeon, Indian Forces Hospital
| | - M B Cook
- Division of Cancer Epidemiology and Genetics, National Cancer Institute(NCI),National Institute of Health(NIH), Bethesda, Maryland, USA
| |
Collapse
|
4
|
Zhang H, Hylander BL, LeVea C, Repasky EA, Straubinger RM, Adjei AA, Ma WW. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. Br J Cancer 2013; 110:320-9. [PMID: 24327018 PMCID: PMC3899776 DOI: 10.1038/bjc.2013.754] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Revised: 10/22/2013] [Accepted: 10/29/2013] [Indexed: 11/20/2022] Open
Abstract
Background: Fibroblast growth factor receptor (FGFR) signalling has been implicated in pancreas carcinogenesis. We investigated the effect of FGFR inhibition in pancreatic cancer in complementary cancer models derived from cell lines and patient-derived primary tumour explants. Methods: The effects of FGFR signalling inhibition in pancreatic cancer were evaluated using anti-FRS2 shRNA and dovitinib. Pancreatic cancers with varying sensitivity to dovitinib were evaluated to determine potential predictive biomarkers of efficacy. Primary pancreatic explants with opposite extreme of biomarker expression were selected from 13 tumours for in vivo dovitinib treatment. Results: Treatment with anti-FRS2 shRNA induced significant in vitro cell kill in pancreatic cancer cells. Dovitinib treatment achieved similar effects and was mediated by Akt/Mcl-1 signalling in sensitive cells. Dovitinib efficacy correlated with FRS2 phosphorylation status, FGFR2 mRNA level and FGFR2 IIIb expression but not phosphorylation status of VEGFR2 and PDGFRβ. Using FGFR2 mRNA level, a proof-of-concept study using primary pancreatic cancer explants correctly identified the tumours' sensitivity to dovitinib. Conclusion: Inhibiting FGFR signalling using shRNA and dovitinib achieved significant anti-cancer cancer effects in pancreatic cancer. The effect was more pronounced in FGFR2 IIIb overexpressing pancreatic cancer that may be dependent on aberrant stimulation by stromal-derived FGF ligands.
Collapse
Affiliation(s)
- H Zhang
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| | - B L Hylander
- Department of Immunity, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| | - C LeVea
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| | - E A Repasky
- Department of Immunity, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| | - R M Straubinger
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA
| | - A A Adjei
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| | - W W Ma
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA
| |
Collapse
|
5
|
Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer 2013; 110:602-8. [PMID: 24292447 PMCID: PMC3915116 DOI: 10.1038/bjc.2013.735] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 10/27/2013] [Accepted: 10/30/2013] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). METHODS This single arm, multicentre phase II trial enrolled patients with previously untreated, locally advanced or metastatic non-squamous NSCLC. Patients received intravenous ziv-aflibercept 6 mg kg(-1), pemetrexed 500 mg m(-2), and cisplatin 75 mg m(-2), every 21 days for up to six cycles. Maintenance administration of ziv-aflibercept was to continue until disease progression, intolerable toxicity or other cause for withdrawal. The co-primary end points were objective response rate (ORR) and progression-free survival (PFS). Planned sample size was 72 patients. RESULTS The study was closed prematurely because of three confirmed and two suspected cases of reversible posterior leukoencephalopathy syndrome (RPLS). A total of 42 patients were enrolled. Median age was 61.5 years; 55% were male, 86% Caucasian and 50% had Eastern Cooperative Oncology Group performance status (ECOG PS)=0. A median of four cycles of ziv-aflibercept was administered. The most common treatment-emergent adverse events (TEAEs) of any grade were nausea (69%) and fatigue (67%), with hypertension (36%) as the most common grade 3/4 TEAE. Of the 38 evaluable patients, ORR was 26% and median PFS was 5 months. CONCLUSION Cases of RPLS had been observed in other studies in the ziv-aflibercept clinical development programme but the rate observed in this study was higher than previously observed. This might be related to declining renal function and/or hypertension. Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC.
Collapse
Affiliation(s)
- H Chen
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA
| | - M R Modiano
- Arizona Oncology/Arizona Clinical Research Center, 1620W. St Mary's Rd, Tucson, AZ 85745, USA
| | - J W Neal
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - J R Brahmer
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting/Blaustein CRB, 1650 Orleans St., G94, Baltimore, MD 21231, USA
| | - J R Rigas
- Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA
| | - R M Jotte
- Rocky Mountain Cancer Centers, 1800 Williams Street, Suite 200, Denver, CO 80218, USA
| | - N B Leighl
- Department of Medicine, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
| | - J W Riess
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - C J Kuo
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| | - L Liu
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - B Gao
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - A T Dicioccio
- Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
| | - A A Adjei
- Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA
| | - H A Wakelee
- Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
| |
Collapse
|
6
|
Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 2013; 109:1085-92. [PMID: 23942080 PMCID: PMC3778312 DOI: 10.1038/bjc.2013.474] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Revised: 06/23/2013] [Accepted: 07/23/2013] [Indexed: 12/31/2022] Open
Abstract
Background: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and antitumour activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, combined with docetaxel in patients with incurable solid tumours. Methods: PX-866 was administered at escalating doses (4–8 mg daily) with docetaxel 75 mg m−2 intravenously every 21 days. Archived tumour tissue was assessed for potential predictive biomarkers. Results: Forty-three patients were enrolled. Most adverse events (AEs) were grade 1 or 2. The most frequent study drug-related AE was diarrhoea (76.7%), with gastrointestinal disorders occurring in 79.1% (docetaxel-related) and 83.7% (PX-866-related). No dose-limiting toxicities were observed. The RP2D was 8 mg, the same as the single-agent MTD. Co-administration of PX-866 and docetaxel did not affect either drug's PKs. Best responses in 35 evaluable patients were: 2 partial responses (6%), 22 stable disease (63%), and 11 disease progression (31%). Eleven patients remained on study for >180 days, including 8 who maintained disease control on single-agent PX-866. Overall median progression-free survival (PFS) was 73.5 days (range: 1–569). A non-significant association between longer PFS for PIK3CA-MUT/KRAS-WT vs PIK3CA-WT/KRAS-WT was observed. Conclusion: Treatment with PX-866 and docetaxel was well tolerated, without evidence of overlapping/cumulative toxicity. Further investigation with this combination is justified.
Collapse
Affiliation(s)
- D W Bowles
- Division of Medical Oncology, School of Medicine, Universitiy of Colorado, 12801 E. 17th Avenue, MS 8117, Aurora, CO 80045, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol 2012; 23:2919-2924. [PMID: 22782333 PMCID: PMC3577038 DOI: 10.1093/annonc/mds123] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 03/12/2012] [Accepted: 03/14/2012] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND This pooled analysis evaluated the outcomes of prophylactic cranial irradiation (PCI) in 739 small-cell lung cancer (SCLC patients with stable disease (SD) or better following chemotherapy ± thoracic radiation therapy (TRT) to examine the potential advantage of PCI in a wider spectrum of patients than generally participate in PCI trials. PATIENTS AND METHODS Three hundred eighteen patients with extensive SCLC (ESCLC) and 421 patients with limited SCLC (LSCLC) participated in four phase II or III trials. Four hundred fifty-nine patients received PCI (30 Gy/15 or 25 Gy/10) and 280 did not. Survival and adverse events (AEs) were compared. RESULTS PCI patients survived significantly longer than non-PCI patients {hazard ratio [HR] = 0.61 [95% confidence interval (CI): 0.52-0.72]; P < 0.0001}. The 1- and 3-year survival rates were 56% and 18% for PCI patients versus 32% and 5% for non-PCI patients. PCI was still significant after adjusting for age, performance status, gender, stage, complete response, and number of metastatic sites (HR = 0.82, P = 0.04). PCI patients had significantly more grade 3+ AEs (64%) compared with non-PCI patients (50%) (P = 0.0004). AEs associated with PCI included alopecia and lethargy. Dose fractionation could be compared only for LSCLC patients and 25 Gy/10 was associated with significantly better survival compared with 30 Gy/15 (HR = 0.67, P = 0.018). CONCLUSIONS PCI was associated with a significant survival benefit for both ESCLC and LSCLC patients who had SD or a better response to chemotherapy ± TRT. Dose fractionation appears important. PCI was associated with an increase in overall and specific grade 3+ AE rates.
Collapse
Affiliation(s)
- S E Schild
- Department of Radiation Oncology, Mayo Clinic, Scottsdale.
| | - N R Foster
- Section of Biomedical Statistics and Informatics, Mayo Clinic, Rochester
| | - J P Meyers
- Section of Biomedical Statistics and Informatics, Mayo Clinic, Rochester
| | - H J Ross
- Division of Medical Oncology, Mayo Clinic
| | - P J Stella
- Michigan Cancer Research Consortium, Ann Arbor
| | - Y I Garces
- Department of Radiation Oncology, Mayo Clinic, Rochester
| | - K R Olivier
- Department of Radiation Oncology, Mayo Clinic, Rochester
| | - J R Molina
- Department of Medical Oncology, Mayo Clinic, Rochester
| | - L R Past
- Department of Radiation Oncology, Luther Hospital Eau Claire
| | - A A Adjei
- Department of Radiation Oncology, Mayo Clinic, Rochester
| |
Collapse
|
8
|
Kulkarni S, Fetterly GJ, Morrison CD, Adjei AA, Andrews C, Edge SP, Mukhopadhyay UK, Swetzig WM, Das GM. OT1-03-03: Effect of Tamoxifen Therapy on Inhibition of Tumor Suppressor p53 by Estrogen Receptor. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot1-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A large number of patients with estrogen receptor (ER)-positive tumors are resistant to tamoxifen (TAM). Although several plausible reasons for such resistance have been suggested, the mechanisms remain unclear. ER mediates effects of estrogen by promoting proliferation of breast cancer cells. Tumor suppressor protein p53 guards against tumorigenesis by preventing proliferation of cells with genomic damage. Dr. Das's laboratory previously reported that ER binds and functionally suppresses wild type p53 in human breast cancer cells and xenograft tumor tissue, and TAM is capable of inhibiting this interaction. We hypothesize that relieving suppression of wild type p53 by ER could be an important mechanism underlying TAM action in breast cancer. To test this hypothesis, we have initiated a pilot randomized clinical trial of 50 women with newly diagnosed ERa-positive breast cancer.
Specific Aims: 1) To investigate the effect of a short pre-surgical intervention with TAM on the ER-p53 interaction in ER-positive, p53 wild type breast tumors and 2) To confirm the wild type status of p53 and analyze the functional status of the p53 pathway by monitoring expression of selected p53 target genes in tumors that have and have not been treated with TAM.
Trial design: A randomized clinical trial in the pre-surgical setting was proposed with either TAM 20mg for four weeks vs. no intervention. Patients randomized to the TAM arm will undergo multiple pharmacokinetic and phamacodynamic measurements of TAM metabolites and genotyping for common polymorphisms of TAM metabolism genes, CYP2D6 and CYP3A4/5. Fresh tumor tissue will be harvested from all patients at the time of surgery for analysis of ER-p53 protein interaction using tissue chromatin immunoprecipitation (tissue ChIP) assay. p53 gene status will be determined by sequencing. RNA and protein expression of ER, p53, and a selected group of ER and p53 target genes in the diagnostic core biopsy and surgical specimens will be analyzed by quantitative real-time PCR (qRTPCR) and immunohistochemistry (IHC). TAM metabolites will also be measured in the tumor and the surrounding benign tissue.
Eligibility criteria: Women greater or equal to eighteen years of age diagnosed with ER-positive invasive breast cancer (approximately 1cm in size) who will undergo primary surgical excision for their initial therapy are eligible. Women must not be pregnant, be on current hormonal therapy, or have a history of hypercoagulable syndrome or prior arterial or venous thrombosis.
Statistical methods: Descriptive statistics such as frequencies and relative frequencies will be computed for all categorical variables. Numeric variables will be summarized using simple descriptive statistics such as mean, standard deviation, and quartiles. Ninety-five percent confidence intervals will be computed. ChIP data will be subjected to Fisher's Exact Test. IHC date will be analyzed by Wilcoxon-Mann-Whitney test.
Present accrual and target accrual: We have accrued 17 patients to date and plan to accrue a total of 50 patients, 25 in each arm.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-03-03.
Collapse
Affiliation(s)
- S Kulkarni
- 1Roswell Park Cancer Institute, Buffalo, NY
| | | | | | - AA Adjei
- 1Roswell Park Cancer Institute, Buffalo, NY
| | - C Andrews
- 1Roswell Park Cancer Institute, Buffalo, NY
| | - SP Edge
- 1Roswell Park Cancer Institute, Buffalo, NY
| | | | - WM Swetzig
- 1Roswell Park Cancer Institute, Buffalo, NY
| | - GM Das
- 1Roswell Park Cancer Institute, Buffalo, NY
| |
Collapse
|
9
|
Ma WW, Messersmith WA, Dy GK, Freas E, Whitworth A, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Pennella EJ, Pohl G, Girvan AC, Winfree K, Martinez B, Obasaju CK, Walker MS, Stepanski EJ, Schwartzberg LS, Adjei AA. Prospective observational comparison of outcomes in African American and Caucasian patients receiving second-line treatment with pemetrexed for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh L, Dubowy RL, Jeffers M, Rajagopalan P, Weekes CD. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Sosman JA, Adjei AA, LoRusso P, Michael SA, Dy GK, Bowditch A, Chmielowski B, Lee S, Walker RM, Faucette S, Izmailova ES, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps145] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, Leighl NB, Adjei AA, Schiller JH. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7013] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Blumenschein GR, Molina JR, Lathia CD, Ong TJ, Roth D, Rajagopalan P, Fossella FV, Kies MS, Marks RS, Adjei AA, Sundaresan PR. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Fetterly GJ, Thudium KE, Kalabus J, Murphy M, Zagst PD, Prey J, Kittleman E, Adjei AA, O'Connor TL, Blanco JG. Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Besse B, Soria J, Gomez-Roca C, Ware JA, Adjei AA, Dy GK, Shankar G, Brachmann RK, Groen HJ. A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3044] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3034] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Schild SE, Foster NR, Meyers JP, Olivier KR, Ross HJ, Molina JR, Stella PJ, Past LR, Garces YI, Adjei AA. Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Mandrekar SJ, Qi Y, Allen-Ziegler K, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA. Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7513] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Adjei AA, Aviyase JT, Tettey Y, Adu-Gyamfi C, Mingle JAA, Ayeh-Kumi PF, Adiku TK, Gyasi RK. Hepatitis E virus infection among pig handlers in Accra, Ghana. ACTA ACUST UNITED AC 2010; 86:359-63. [PMID: 20575309 DOI: 10.4314/eamj.v86i8.54155] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To determine the correlates of hepatitis E virus infection (HEV) in a sample of persons who work with pigs. DESIGN Cross-sectional study. SETTING Three pig farms in the Greater Accra Region of Ghana. SUBJECTS Persons who work with pigs seen at the selected pig farms between the months of January and May 2008. RESULTS One hundred and five persons who work with pigs voluntarily completed a risk-factor questionnaire and provided blood samples for unlinked anonymous testing for the presence of antibodies to HEV. The median age of participants was 36.5 +/- 15.0 years (range 12-65 years). Of the 105 subjects tested, HEV seroprevelance was 38.1%. On multivariate analysis, the independent determinants of HEV infection were being employed on the farm for less than six months (odds ratio (OR) 9.1; 95% confidence interval (95% CI) 1.0-81.4 and having piped water in the household and/or on the farm (OR 3.9; 95% CI 0.4-90.8). CONCLUSION Consistent with similar studies worldwide, the results of our studies revealed a high prevalence of HEV infection in persons who work with pigs. Further studies need to be done to isolate, characterise the virus and define the clinical and epidemiological significance of HEV infection in this population.
Collapse
Affiliation(s)
- A A Adjei
- Department of Pathology, University of Ghana Medical School, College of Health Sciences, Accra, Ghana
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol 2010; 21:2040-2044. [PMID: 20570832 DOI: 10.1093/annonc/mdq075] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC. PATIENTS AND METHODS Older patients [≥ 65 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2] or younger patients (performance status of 2) received cetuximab 400 mg/m(2) i.v. on day 1 followed by weekly cetuximab 250 mg/m(2) i.v. with concomitant radiation of 6000 cGy in 30 fractions. The primary end point was the percentage who lived 11+ months. RESULTS This 57-patient cohort had a median age (range) of 77 years (60-87), and 12 (21%) had a performance status of 2. Forty of 57 (70%) lived 11+ months, thus exceeding the anticipated survival rate of 50%. The median survival was 15.1 months [95% confidence interval (CI) 13.1-19.3 months], and the median time to cancer progression was 7.2 months (95% CI 5.8-8.6 months). No treatment-related deaths occurred, but 31 patients experienced grade 3+ adverse events, most commonly fatigue, anorexia, dyspnea, rash, and dysphagia, each of which occurred in <10% of patients. CONCLUSION This combination merits further study in this group of patients.
Collapse
Affiliation(s)
- A Jatoi
- Mayo Clinic Rochester, Rochester, MN.
| | | | - N Foster
- Mayo Clinic Rochester, Rochester, MN
| | | | - K J Dornfeld
- Duluth City Clinical Oncology Program, Duluth, MN
| | - P J Flynn
- Metro-Minnesota Community Oncology Program, St Louis Park, MN
| | | | - S R Dakhil
- Wichita Community Clinical Oncology Program, Wichita, KS
| | - K M Rowland
- Carle Cancer Center City Clinical Oncology Program, Urbana, IL
| | - P J Stella
- Michigan Cancer Consortium, Ann Arbor, MI
| | - G S Soori
- Missouri Valley Cancer Consortium, Omaha, NE
| | - A A Adjei
- Roswell Park Cancer Institute, Buffalo, NY, USA
| |
Collapse
|
23
|
Calvo E, Ma W, Tolcher AW, Hidalgo M, Soria J, Bahleda R, Gualberto A, Denis LJ, Millham RD, Adjei AA. Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Mandrekar SJ, Hillman SL, Allen-Ziegler K, Jatoi A, Jett JR, Schild SE, Adjei AA. Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Schild SE, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Foster NR, Adjei AA. N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Dy GK, Mandrekar SJ, Nelson GD, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7603] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Ma W, Mani S, Freas E, Dy GK, Ghalib MH, Messersmith WA, Bellemarre S, Wilhelm F, Adjei AA, Jimeno A. Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H. Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e16505] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Adjei AA, Sosman JA, Dy GK, Ma W, Fetterly GJ, Skupien D, Means JA, Savage R, Chai F, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Pennella EJ, Peltz G, Girvan AC, Pohl G, Faries DE, Marciniak MD, Obasaju CK, Stepanski EJ, Schwartzberg L, Adjei AA. Interim results of an observational study evaluating the impact of ethnic origin on the effect of second-line treatment with pemetrexed (P) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Qi Y, Dy GK, Nelson GD, Schild SE, Mandrekar SJ, Adjei AA. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2009; 29:1190-202. [PMID: 19935717 DOI: 10.1038/onc.2009.403] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF). In addition, the Ras/Raf/MEK/ERK pathway is critical for the proliferation of myeloma cells and is often upregulated. Sorafenib (Nexavar) is a novel multi-kinase inhibitor that acts predominantly through inhibition of Raf-kinase and VEGF receptor 2, offering the potential for targeting two important aspects of disease biology. In in vitro studies, sorafenib-induced cytotoxicity in MM cell lines as well as freshly isolated patient myeloma cells. It retained its activity against MM cells in co-culture with stromal cells or with interleukin-6, VEGF or IGF; conditions mimicking tumor microenvironment. Examination of cellular signaling pathways showed downregulation of Mcl1 as well as decreased phosphorylation of the STAT3 and MEK/ERK, as potential mechanisms of its anti-tumor effect. Sorafenib induces reciprocal upregulation of Akt phosphorylation; and simultaneous inhibition of downstream mTOR with rapamycin leads to synergistic effects. Sorafenib also synergizes with drugs such as proteasome inhibitors and steroids. In a human in vitro angiogenesis assay, sorafenib showed potent anti-angiogenic activity. Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations.
Collapse
Affiliation(s)
- V Ramakrishnan
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Girvan AC, Peltz G, Pennella E, Pohl G, Faries D, Marciniak MD, Obasaju CK, Stepanski EJ, Schwartzberg LS, Adjei AA. An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20624 Background: African-Americans are more likely to develop and die from lung cancer than persons of any other ethnic group. Historically, African-Americans have been under-represented in oncology clinical research. This prospective, single-arm, observational study evaluates the impact of ethnicity on disease control rate (DCR) (CR + PR + SD)) in patients (pts) with non-small lung cancer (NSCLC) being treated with pemetrexed (Pem) in the second-line setting. Methods: Eligibility criteria include stage IIIB or IV NSCLC pts receiving Pem for second-line therapy with no restrictions on performance status. An accrual of 200 African-Americans, 200 Hispanics, 200 Asian-Americans, and 400 Caucasians is planned to test the hypothesis that subjects from these minority populations with advanced NSCLC will have DCRs that are not inferior to Caucasian subjects during second-line treatment with Pem in routine clinical practice. This report describes observations from an early examination of the data of the Caucasian and African-American pts enrolled. Results: 293 pts have been enrolled in this study including 243 Caucasians and 34 African-Americans. Demographics of Caucasians: M/F (136:107); median age 66 (range 37–88); histology adenocarcinoma/squamous/other/unknown (141:67:33:2). Demographics of African-Americans: M/F (21:13); median age 64 (range 43–80); histology adenocarcinoma/squamous/other/unknown (22:9:3:0). DCR in Caucasians: 38% (CI= 28–47%: 3 CR, 8 PR, and 34 SD in 120 of the 243 pts). DCR in African-Americans: 61% (CI=36–86%: 0 CR, 0 PR, and 11 SD in 18 of the 34 pts). Updated safety and efficacy data will be available. Conclusions: Preliminary results based on limited data do not indicate an inferior response for African-American pts compared to Caucasian pts being treated with Pem for NSCLC in the second-line setting. Additional data are needed to establish a definitive conclusion. [Table: see text]
Collapse
Affiliation(s)
- A. C. Girvan
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - G. Peltz
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - E. Pennella
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - G. Pohl
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - D. Faries
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - M. D. Marciniak
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - C. K. Obasaju
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - E. J. Stepanski
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - L. S. Schwartzberg
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| | - A. A. Adjei
- Eli Lilly, Indianapolis, IN; Accelerated Community Oncology Research Network, Memphis, TN; The West Clinic, Memphis, TN; Roswell Park Cancer Institute, Buffalo, NY
| |
Collapse
|
35
|
Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A. Results of a phase I trial of KX2–391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3511] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells. KX2–391 is a synthetic, orally bioavailable small molecule Src tyrosine kinase signaling inhibitor. KX2–391 is distinct from all other known Src kinase inhibitors in targeting the peptide substrate-binding site and not the ATP-binding site. KX2–391 is the first peptide site targeted tyrosine kinase inhibitor to enter clinical trials. KX2–391 has a much wider spectrum of solid tumor activity in vitro, and is more potent in mouse xenografts, as compared to other multikinase Src/Abl inhibitors. Methods: This multi-center Phase 1 trial utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2–391 in pts with refractory solid tumors. Results: To date, 32 pts (12 m 20 f, median age 59 (range 31–78)) have been enrolled in 7 dose cohorts. Dose limiting toxicities (DLTs), which were all reversible within 7 days, occurred in 4 pts and included elevated ALT and AST, neutropenia, and fatigue. 22 pts experienced no Grade 3 or 4 adverse events. Other Grade 1/2 adverse events include: hypokalemia, anemia, elevated AST, fatigue, dyspnea, fever, vomiting, constipation, hematuria, and lymphopenia. The MTD is 40 mg BID on a 3 out of 4 weeks dosing schedule. 7 pts had prolonged stable disease for 4 months or longer including 2 pts with papillary thyroid carcinoma, 2 with carcinoid, and 1 each with prostate, pancreas, and head and neck cancer. Both the prostate and pancreatic cancer pts had dramatic decreases in their biomarkers (PSA went from 205 ng/ml to 39 ng/ml, and CA19–9 went from 38,838 U/ml to 267 U/ml, respectively). The PK profile demonstrated dose-proportionality, a half-life of 4.5 hrs and a Tmax of 1 hr with no evidence of accumulation with multiple doses. Conclusions: KX2–391 has a favorable PK profile, is well-tolerated, demonstrates preliminary evidence of biologic activity and should be further evaluated in Phase II trials. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- A. A. Adjei
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - R. B. Cohen
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - R. Kurzrock
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - G. S. Gordon
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - D. Hangauer
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - L. Dyster
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - G. Fetterly
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - S. Barrientes
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - D. S. Hong
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| | - A. Naing
- Roswell Park Cancer Institute, Buffalo, NY; Fox Chase Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; Kinex Pharmaceuticals, Buffalo, NY; Roswell Park Cancer Institute, Buffalo, NY
| |
Collapse
|
36
|
Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8085 Background: Historically, tumor response has been the primary endpoint in phase II (P2) trials in ED-SCLC. We investigated the suitability of alternate PFS based endpoints to predict OS as early evidence of efficacy in the P2 setting. Methods: Individual patient (pt) data from 942 pts from 11 previously untreated ED-SCLC P2 and phase III (P3) platinum- or paclitaxel-based treatment trials were pooled. Best response (BR), response confirmed (RC), objective status at 16 weeks (RR16), and PFS rate at 5 and 6 months were considered. Percent agreement (PA) and kappa (k) for PFS5, PFS6, BR, RC, and RR16 with OS at 12 months (OS12) was calculated on a per-pt basis and predictive utility was assessed using the area under the receiver operating characteristic (A- ROC) curve in logistic models. Cox models were used to assess the prognostic impact of the endpoints on subsequent survival, using landmark analysis. Results: The median OS and PFS were 9.6 m and 5.5 m, respectively. PFS5 and PFS6 had the highest PA, k, and A-ROC values, and were predictive of subsequent survival in the landmark analysis (p <0.0001; c-statistics ≥ 0.60). While RR16 and BR were significantly associated with subsequent survival (p<0.0001, c-statistics of 0.61 and 0.57, respectively) the PA, k, and A-ROC values were lower. Conclusions: PFS rate at 5 and 6 months is more predictive of 12-month OS and subsequent survival than tumor response in untreated ED-SCLC. PFS based endpoints should be routinely used as primary endpoints in P2 trials within ED-SCLC. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. R. Foster
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - Y. Qi
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - J. E. Krook
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - J. W. Kugler
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - S. A. Kuross
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - J. R. Jett
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - J. R. Molina
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - S. E. Schild
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - A. A. Adjei
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - S. J. Mandrekar
- Mayo Clinic, Rochester, MN; Duluth Clinic, Duluth, MN; Illinois CancerCare, Peoria, IL; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| |
Collapse
|
37
|
Mandrekar SJ, Hillman SL, Ziegler KLA, Reuter NF, Rowland KM, Marks RS, Schild SE, Adjei AA. Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Schild SE, Qi Y, Tan AD, Mandrekar SJ, Adjei AA, Krook JE, Rowland KM, Garces YI, Soori GS, Sloan JA. Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8076] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Jett JR, Bernath AM, Foster NR, Molina JR, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM, Fitch TR, Adjei AA. Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Campbell ME, Mandrekar SJ, Hillman SL, Goldberg RM, Adjei AA, Pitot HC, Rowland KM, Grothey A, Buckner JC, Sargent DJ. What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland Jr KM, Deming RL, Kozelsky TF, Jett JR, Marks RS, Adjei AA. Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Dy GK, Croghan GA, Qi Y, Glockner J, Hanson L, Roos M, Tan AD, Molina JR, Adjei AA. Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Kumar S, Marks RS, Richardson R, Quevedo F, Croghan GA, Markovic SN, Qin R, Tan AD, Molina JR, Erlichman CE, Adjei AA. A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KLA, Stella PJ, Rowland KM, Schild SR, Zinner RG. A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8080] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA. The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19503 Background: This study was performed to assess the value of combined modality therapy in elderly patients by comparing the differences in outcome of those who received radiotherapy (RT) alone or RT plus chemotherapy for stage III NSCLC. Methods: North Central Cancer Treatment Group (NCCTG) performed 2 recent phase III trials for stage III NSCLC. The first trial, 90–24–51, included 3 arms: once-daily radiotherapy (QDRT) alone, twice daily RT (BIDRT) alone, and concurrent chemotherapy plus BIDRT. The second trial, 94–24- 52 included 2 arms and compared concurrent chemotherapy with either QDRT or BIDRT. The chemotherapy arms of both trials included etoposide and cisplatin administered concurrently with RT. Only the patients ≥65 years of age (elderly) who participated in these trials were included in this analysis. Results: Of the 166 elderly patients included in this analysis, 37 received RT alone and 129 received concurrent chemotherapy plus RT. The median and 5-year survival rates were 10.5 months and 5.4% for the RT alone group compared to 13.7 months and 14.7% for the RT plus chemotherapy group (log-rank p=0.05). Patients who received RT plus chemotherapy experienced significantly greater severe (grade ≥3) toxicity than those who received RT alone (89.9% versus 32.4%, p < 0.01). Conclusions: Elderly patients who participated in these trials appear to gain a survival advantage from RT and chemotherapy compared to RT alone. As is the case with younger patients, this benefit comes at the cost of additional toxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. E. Schild
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - S. J. Mandrekar
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - A. Jatoi
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - W. L. McGinnis
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - P. J. Stella
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - R. L. Deming
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - J. R. Jett
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - Y. I. Garces
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - K. L. Allen
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| | - A. A. Adjei
- Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Michigan Cancer Research Consortium, Ann Arbor, MI; Iowa Oncology Research Association CCOP, Des Moines, IA
| |
Collapse
|
46
|
Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA, Roberts ML, Gualberto A, de Bono JS. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3586] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3586 Background: The insulin-like growth factor 1 receptor (IGF-IR), a tyrosine kinase, and its ligands (IGF-I & -2) are upregulated in many human tumors (e.g., breast, prostate, colon and non-small cell lung cancer) and enhance proliferative and prosurvival signaling. Inhibition of IGF-IR activation in tumor models suppresses tumor growth and increases tumor sensitivity to chemotherapy, supporting the development of agents targeting IGF-IR. CP-751,871 is a potent, highly specific, fully humanized, monoclonal antibody that inhibits IGF-IR autophosphorylation and induces receptor internalization. Methods: A Phase I dose escalation study was initiated to define the safety and tolerability, and to characterize the pharmacokinetic properties of CP-751,871 in patients with advanced solid tumors refractory to standard therapies. Results: Following informed consent and screening, a total of 24 patients with refractory solid tumors (e.g. colorectal, NSCLC, sarcoma and prostate cancer; 1–6 previous regimens) were enrolled. Patients received 3 to 20 mg/kg of CP-751,871 by IV infusion on Day 1 of 3-week cycles in four dose-escalation cohorts of 3 patients. No dose limiting toxicities were identified and the maximum feasible dose (MFD) cohort of 20 mg/kg was extended with 12 additional patients. No higher than grade 3 CTCAE v3.0 toxicities, attributed to study drug, have been so far reported. Grade 3 toxicities, all reported in patients dosed with 20 mg/kg of CP-751,871, are increased GGT (4%) and fatigue (4%). Grade 2 toxicities include: anorexia (7%), diarrhea (7%), increased GGT (4%), hyperglycemia (4%), fatigue (4%), increased urinary frequency (4%), nausea (4%), increased ALT (4%) and increased AST (4%). Pharmacokinetic analysis is currently ongoing. No objective responses were observed. At the MFD, patients received a median of 4 cycles (1–16). Three patients were stable for > 6 months and one patient, currently at cycle 16, remains on study. An additional cohort of 12 adrenocortical cancer patients is under evaluation. Conclusions: These data indicate that CP-751,871 is safe and well tolerated. Due to its good safety profile, CP-751,871 may constitute a suitable targeted agent to use in combination with approved therapies in multiple tumor types. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Haluska
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - H. Shaw
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - G. N. Batzel
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - L. R. Molife
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - A. A. Adjei
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - T. A. Yap
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - M. L. Roberts
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - A. Gualberto
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| | - J. S. de Bono
- Mayo Clinic, Rochester, MN; Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Roswell Park Cancer Institute, Buffalo, NY; Pfizer Global Research & Development, New London, CT
| |
Collapse
|
47
|
Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jett JR, Mandrekar SJ, Schild SE. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7547] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7547 Background: Sorafenib is a multikinase inhibitor with single-agent activity in previously treated NSCLC. In an effort to evaluate its single agent activity in previously untreated NSCLC, the NCCTG undertook a front-line “window of opportunity” study. Materials and Methods: Patients with stage IIIB (pleural effusion) or stage IV NSCLC received sorafenib dosed at 400 mg BID continuously, with a cycle defined as 4 weeks. Patients were evaluated weekly during the first 2 cycles with those who progressed rapidly going on to receive standard chemotherapy. Based on a two-stage Fleming design, if only at most 1 confirmed response was observed in the first 20 patients enrolled to stage I, the regimen would be considered ineffective. If 2 or more responses were observed, the study would proceed to stage 2 and accrue an additional 22 patients. If 5 or more confirmed responses were observed, the regimen would be recommended for further testing. Results: The study did not meet the stage I efficacy criteria (only 1 confirmed partial response in the first 20 patients) and was permanently closed after enrolling 25 evaluable patients [15 females, 10 males; 4 stage IIIB, 21 stage IV; median age 67 (45–85)]. 2 patients are still receiving treatment (14 and 15 months). No grade 3 or higher hematologic adverse events were observed. Thirteen (52%) patients had a grade 3 non-hematologic adverse event with fatigue (20%), diarrhea (8%), and dyspnea (8%) being the most common. There was one grade 4 pulmonary hemorrhage. A total of 3 (12%) PRs; and 7 (28%) SD were observed in the 25 patients 7 (28%) patients were progression- free at 24 weeks. Median survival and median time to progression were 8.8 and 2.9 months respectively. Conclusion: While the pre- specified efficacy endpoints were not met, the objective response rate of 12% and median survival of 8.8 months suggest that single agent sorafenib has activity similar to two-drug combinations. The feasibility and utility of the “window of opportunity” design in estimating the activity of novel compounds was demonstrated. Finally, the single-agent activity of sorafenib argues for combination studies with standard chemotherapy agents. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. A. Adjei
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - J. R. Molina
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. L. Hillman
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - R. F. Luyun
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - N. F. Reuter
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - K. M. Rowland
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - J. R. Jett
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. J. Mandrekar
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| | - S. E. Schild
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic, Rochester, MN; Carle Cancer Center, Urbana, IL; CentraCare Clinic, St. Cloud, MN; Mayo Clinic College of Medicine, Scottsdale, AZ
| |
Collapse
|
48
|
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Jett JR, Adjei AA. Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: A pooled analysis of 1,623 patients from the North Central Cancer Treatment Group. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7723] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7723 Background: It is critical that we understand the impact of patient, tumor, and treatment-related factors on patient prognosis for the proper design and analysis of Small Cell Lung Cancer (SCLC) trials. An analysis of 15 SCLC trials was performed to investigate and improve our understanding of several factors on OS. Methods: Data from 1623 patients (pts) were used. Age, gender, performance status (PS), tumor stage, body mass index (BMI), creatinine levels, hemoglobin levels, white blood cell counts (WBC), platelet counts, and bilirubin levels were tested for prognostic significance for OS both univariately and multivariately using a Cox Proportional Hazards Model. Models were stratified by protocol, and analyses carried out on the complete data available based on the selected covariates. Model discrimination (i.e., ability to discriminate patients with different survival times) was evaluated using the concordance index (COI). Results: Median follow-up was 63.1 months (range: 1.9 to 155.7). 58% and 42% of pts had extensive-stage or limited-stage SCLC, respectively. Patients with extensive-stage disease, PS>0, increased age, and male gender had significantly worse OS both univariately and multivariately. Patients with increased WBC had significantly worse OS univariately, however, WBC was not a significant predictor when adjusted for other factors. None of the other factors were prognostic for OS. Model discrimination improved by 6.3% when age, gender, PS, and stage were included in a model compared to a model with stage alone (COI improved from 0.63 to 0.67). Conclusions: Age, gender, PS and stage did better at predicting OS than stage alone. Further refinement of this model, including the addition of number of metastatic sites at baseline and treatment related factors, is currently underway. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- N. R. Foster
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - S. J. Mandrekar
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - S. E. Schild
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - G. D. Nelson
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - J. R. Jett
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| | - A. A. Adjei
- Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Roswell Park Cancer Institute, Buffalo, NY
| |
Collapse
|
49
|
Adjei AA, Adiku TK, Ayeh-Kumi PF, Hesse IFA. Prevalence of human immunodeficiency virus infection among tuberculosis suspect patients in Accra, Ghana. West Afr J Med 2006; 25:38-41. [PMID: 16722357 DOI: 10.4314/wajm.v25i1.28243] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Acquired immunodeficiency syndrome is a major public health concern worldwide, particularly in Ghana, where recent reports indicate an increase of the disease. A close association between infection with human immunodeficiency virus (HIV) and tuberculosis (TB) is well known. A previous study showed a 16.8% seroprevalence of HIV in TB patients on admission at the chest clinic of the Korle-Bu teaching hospital. However this was in severely ill patients on admission and there was a likely selection bias. This study was therefore designed to determine the prevalence of HIV infection among patients suspected of TB attending the laboratory of the chest clinic of the Korle-Bu Teaching hospital, Accra, Ghana. METHODS Pulmonary TB was diagnosed using clinical, sputum smear microscopy and chest x-ray features. HIV was determined using particle agglutination test (HIV-1 and HIV-2) and synthetic peptide-based immunoassay (Peptilav I and II ELISA). RESULTS Of the 277 subjects examined, 108 (39%) were diagnosed as TB. The seroprevalence of HIV was 46.2% in all TB suspect patients. It was 47.2% and 45.6% in those with and without tuberculosis, respectively. in both groups, the peak age distribution of subjects positive for HIV antibodies was from 20 to 59 years. CONCLUSION The results show a great increase in HIV seroprevalence in TB patients in Korle-Bu. The high HIV seroprevalence suggests that subjects suspected of TB should be tested for HIV as well.
Collapse
Affiliation(s)
- A A Adjei
- Department of Pathology, University of Ghana Medical School, Korle-Bu, Ghana.
| | | | | | | |
Collapse
|
50
|
Yang P, Mandrekar SJ, Hillman SL, Allen KL, Sun Z, Wampfler J, Cunningham JM, Jett JR, Adjei AA, Perez EA. Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97–24–51 based study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13013 Background: The glutathione metabolic pathway is directly involved in the inactivation of platinum compounds. Our earlier work indicated that genotypes corresponding to varied glutathione-related enzyme activities may predict survival in patients with advanced lung cancer. Herein, we evaluated the role of glutathione-related genotypes on clinical outcomes in stage IIIB/IV non-small cell lung cancer patients who were stable or responding from one prior platinum-based chemotherapy. Methods: DNA samples from patients who had tumor regression or stable disease after treatment with one platinum based chemotherapy regimen were analyzed using 6 polymorphic DNA markers that encode 5 important enzymes in the glutathione metabolic pathway. The contrasting genotypes used in the analysis were GCLC (homozygous repeat 77 vs. heterozygous 7*), GPX1 (CC vs. other), GSTP1-I105V (AA vs. other), GSTP1-A114V (CC vs. other), GSTM1 (null vs. present), and GSTT1 (null vs. present). Multivariable Cox proportional hazards models adjusted for age, gender, treatment arm, ECOG performance status, stage, and prior tumor response, were used to evaluate the prognostic significance of the genotypes at each locus. Results: Data from 112 patients with a median follow-up of 10.6 (range: 0.4–56.3) months was used. No significant difference in time to disease progression was observed for any of the genotypes. Among the 6 genomic DNA markers, the GCLC genotype was an important prognostic factor for overall survival after adjusting for other factors. In particular, patients carrying a 77 repeat genotype (homozygous) had a significantly worse survival (Hazard ratio = 1.67, 95% CI: 1.05–2.63). Conclusions: Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients’ prognosis after platinum-based chemotherapy. Further investigation to define and measure the effects of these genes in chemotherapeutic regimens is needed. (This work was partly supported by NIH research grants CA77118, CA80127, and CA84354.) No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Yang
- Mayo Clinic College of Medicine, Rochester, MN
| | | | | | - K. L. Allen
- Mayo Clinic College of Medicine, Rochester, MN
| | - Z. Sun
- Mayo Clinic College of Medicine, Rochester, MN
| | - J. Wampfler
- Mayo Clinic College of Medicine, Rochester, MN
| | | | - J. R. Jett
- Mayo Clinic College of Medicine, Rochester, MN
| | - A. A. Adjei
- Mayo Clinic College of Medicine, Rochester, MN
| | - E. A. Perez
- Mayo Clinic College of Medicine, Rochester, MN
| |
Collapse
|